Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

NCT00803374 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: AntiCD137
DRUG: AntiCD137
DRUG: AntiCD137
DRUG: AntiCD137
DRUG: AntiCD137
DRUG: Ipilimumab

Sponsor

Bristol-Myers Squibb